Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,347 result(s) found. Displaying page 1,186 of 2,218.
    EudraCT Number: 2011-001952-12 Sponsor Protocol Number: CAFQ056B2279 Start Date*: 2011-11-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label study to evaluate the long-term safety, tolerability and efficacy of AFQ056 in adult patients with Fragile X Syndrome
    Medical condition: Fragile X Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) GB (Prematurely Ended) DK (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000966-40 Sponsor Protocol Number: EC-FV-07 Start Date*: 2012-07-04
    Sponsor Name:Endocyte, Inc.
    Full Title: A Randomized, Open-Label Phase 2 Study of EC145 Single-agent and the Combination of EC145 plus Docetaxel Versus Docetaxel Alone in Participants with Folate-Receptor Positive [FR(++)] Second Line NSCLC
    Medical condition: Second line FR(++) non-small cell lung cancer (adenocarcinoma, squamous, adenosquamous, or adenocarcinoma with other NSCLC variants of the lung) (Stage IIIB or IV).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10025054 Lung cancer non-small cell stage IIIB LLT
    14.1 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) GB (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001251-40 Sponsor Protocol Number: MEA115588 Start Date*: 2012-10-16
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncon...
    Medical condition: Subjects with severe, refractory, uncontrolled asthma with elevated blood eosinphils
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-003810-18 Sponsor Protocol Number: H9X-MC-GBDE Start Date*: 2012-07-11
    Sponsor Name:Eli Lilly & Company
    Full Title: A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Once-Daily Liraglutide in Patients with Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRati...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) DE (Completed) PL (Completed) ES (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001616-33 Sponsor Protocol Number: MEM-MD-91 Start Date*: 2012-11-14
    Sponsor Name:Forest Research Institute, Inc.
    Full Title: An Open-Label Study Of The Safety And Tolerability Of Memantine In Pediatric Patients With Autism, Asperger’s Disorder, Or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
    Medical condition: Autism or Asperger’s Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10003484 Asperger's disorder PT
    14.1 10029205 - Nervous system disorders 10008520 Childhood autism LLT
    14.1 10037175 - Psychiatric disorders 10034739 Pervasive developmental disorder NOS LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) IS (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004023-20 Sponsor Protocol Number: CLDE225X2116 Start Date*: 2013-06-21
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A Phase Ib/II, open-label, multi-center, dose-finding study to assess the safety and efficacy of the oral combination of LDE225 and INC424 (Ruxolitinib) in patients with myelofibrosis
    Medical condition: myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Prematurely Ended) IE (Prematurely Ended) IT (Completed) DE (Completed) NL (Prematurely Ended) FR (Prematurely Ended) DK (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002338-35 Sponsor Protocol Number: 144 Start Date*: 2013-05-06
    Sponsor Name:Biosense Webster, Inc.
    Full Title: ATrial FibrillaTion ProgrESsion Trial (ATTEST Trial)
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    16.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) ES (Completed) IE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000691-15 Sponsor Protocol Number: B1871040 Start Date*: 2013-07-08
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008
    Medical condition: Chronic Myeloid Leukemia (CML)
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) HU (Completed) LT (Prematurely Ended) LV (Completed) NL (Completed) FI (Completed) ES (Completed) GB (Completed) FR (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003132-79 Sponsor Protocol Number: EFC12405 Start Date*: 2014-01-21
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A randomized, 30-week, active-controlled, open label, 2-treatment arm, parallel-group, multicenter study comparing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combinati...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) SE (Completed) LT (Completed) CZ (Completed) NL (Completed) ES (Completed) HU (Completed) SK (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000055-41 Sponsor Protocol Number: CV185-220 Start Date*: 2013-08-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
    Medical condition: Patients with Non-Valvular Atrial Fibrillation with at least one risk factor for stroke and indicated for oral anticoagulant.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003879-37 Sponsor Protocol Number: 42160443PAI3002 Start Date*: 2015-07-17
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects with Signs and Symptoms of Osteo...
    Medical condition: Osteoarthritis of the Hip or Knee
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004859 10023476 Knee osteoarthritis LLT
    18.1 100000004859 10020108 Hips osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-005215-33 Sponsor Protocol Number: CLJN452A2202 Start Date*: 2016-06-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, 3- part, adaptive design, multicenter study to assess safety, tolerability and efficacy of tropifexor (LJN452) in patients with non-alcoholic steatoh...
    Medical condition: Non-alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed) DE (Completed) NL (Completed) BE (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001233-27 Sponsor Protocol Number: PI2016_843_0008 Start Date*: 2016-11-03
    Sponsor Name:CHU Amiens Picardie
    Full Title: Efficacity and safety of metformin extended release (XR) in diabetic patients with CKD in stages 1 to 3 (METXR/CKD)
    Medical condition: type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004247-37 Sponsor Protocol Number: 38RC16.046 Start Date*: 2017-05-04
    Sponsor Name:University Hospital Grenoble
    Full Title: NA
    Medical condition: coagulopathy secondary to traumatic hemorrhagic shock
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002470-20 Sponsor Protocol Number: SANNI-project:01 Start Date*: 2017-04-11
    Sponsor Name:Skåne University Hospital
    Full Title: Fentanyl and Clonidine for analgesia during hypothermia in term asphyxiated infants – a prospective pharmacokinetic/ pharmacodynamic/ pharmacogenetic observational study. Cohort 1 in The SANNI proj...
    Medical condition: Infants with induced hypothermic treatment after perinatal asphyxia
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004405-64 Sponsor Protocol Number: MT-2-03 Start Date*: 2019-03-07
    Sponsor Name:Minoryx Therapeutics BE, SA
    Full Title: A Double-Blind, Placebo-Controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological, and Clinical Markers in Patients with Friedreich’s Ataxia
    Medical condition: Friedreich’s Ataxia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10017374 Friedreich's ataxia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005319-33 Sponsor Protocol Number: BuS2020 Start Date*: 2021-09-22
    Sponsor Name:Fundación Cínic per a la Reserca Biomèdica
    Full Title: EFFICACY AND SAFETY OF THE INTRATRACHEAL ADMINISTRATION OF BUDESONIDE WITH SURFACTANT IN VERY PRETERM INFANTS TO PREVENT BRONCHOPULMONARY DYSPLASIA: RANDOMIZED CLINICAL TRIAL
    Medical condition: Bronchopulmonary dysplasia of prematurity
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006475 Bronchopulmonary dysplasia PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005709-50 Sponsor Protocol Number: 1122005 Start Date*: 2006-05-05
    Sponsor Name:Cardiology, University of Frankfurt
    Full Title: Extracorporal shock wave therapy for induction of therapeutic neovascularization and homing of bone marrow progenitor cells in patients with chronic ischemic heart disease
    Medical condition: Patients with ischemic coronary artery disease (congestive heart failure) and s/p anterior myocardial infarction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001778-21 Sponsor Protocol Number: A4001028 Start Date*: 2005-02-02
    Sponsor Name:PFIZER LTD
    Full Title: A multicentre, randomised, double-blind, placebo-controlled trial of a novel CCR5 antagonist, UK-427,857 in combination with optimised background therapy versus optimised background therapy alone f...
    Medical condition: UK-427,857 is an antagonist of the human chemokine receptor, and is intended to help prevent the development and progression of AIDS in indivuduals HIV-1 positive.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-005276-16 Sponsor Protocol Number: ET743-OVA-301 Start Date*: 2005-10-27
    Sponsor Name:Pharma Mar S.A.
    Full Title: An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer.
    Medical condition: Advanced relapsed ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 07:23:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA